Single Subject Neratinib in Bladder Cancer
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Neratinib (Primary)
- Indications Bladder cancer
- Focus Expanded access; Therapeutic Use
- 01 Jul 2016 Status changed from active, no longer recruiting to completed.
- 10 Oct 2013 New trial record